SunTrust Banks, Inc. set a $105.00 price objective on Quest Diagnostics Incorporated (NYSE:DGX) in a research report report published on Sunday. The brokerage currently has a hold rating on the medical research company’s stock. SunTrust Banks also issued estimates for Quest Diagnostics’ Q3 2017 earnings at $1.34 EPS and FY2017 earnings at $5.61 EPS.

Other research analysts also recently issued reports about the stock. UBS AG boosted their price objective on shares of Quest Diagnostics from $115.00 to $123.00 and gave the company a buy rating in a research report on Thursday, July 6th. Evercore ISI restated an in-line rating and set a $104.50 price objective on shares of Quest Diagnostics in a research report on Wednesday, June 28th. Barclays PLC restated a hold rating and set a $110.00 price objective on shares of Quest Diagnostics in a research report on Wednesday, July 19th. BidaskClub upgraded shares of Quest Diagnostics from a sell rating to a hold rating in a research report on Tuesday, August 15th. Finally, Zacks Investment Research downgraded shares of Quest Diagnostics from a buy rating to a hold rating in a research report on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $108.39.

Quest Diagnostics (NYSE DGX) opened at 92.18 on Friday. The stock has a 50 day moving average price of $99.98 and a 200-day moving average price of $104.83. The firm has a market capitalization of $12.57 billion, a PE ratio of 18.58 and a beta of 0.66. Quest Diagnostics has a one year low of $79.12 and a one year high of $112.97.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.13. The business had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.94 billion. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.34 earnings per share. On average, equities analysts forecast that Quest Diagnostics will post $5.63 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “SunTrust Banks, Inc. Analysts Give Quest Diagnostics Incorporated (DGX) a $105.00 Price Target” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/suntrust-banks-inc-analysts-give-quest-diagnostics-incorporated-dgx-a-105-00-price-target/1637522.html.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 18th. Stockholders of record on Tuesday, October 3rd will be issued a dividend of $0.45 per share. The ex-dividend date is Monday, October 2nd. This represents a $1.80 annualized dividend and a dividend yield of 1.95%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 36.29%.

In other news, Director Jeffrey M. Leiden sold 1,304 shares of the company’s stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $108.73, for a total transaction of $141,783.92. Following the completion of the transaction, the director now directly owns 6,296 shares in the company, valued at $684,564.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel Stanzione sold 3,803 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $108.01, for a total transaction of $410,762.03. Following the transaction, the director now owns 35,359 shares of the company’s stock, valued at $3,819,125.59. The disclosure for this sale can be found here. Insiders have sold 161,996 shares of company stock valued at $17,517,207 over the last quarter. Company insiders own 1.75% of the company’s stock.

Several large investors have recently made changes to their positions in DGX. Wellington Management Group LLP increased its holdings in shares of Quest Diagnostics by 77.0% during the first quarter. Wellington Management Group LLP now owns 369,359 shares of the medical research company’s stock worth $36,268,000 after buying an additional 160,723 shares in the last quarter. FMR LLC increased its holdings in Quest Diagnostics by 2.4% in the first quarter. FMR LLC now owns 759,611 shares of the medical research company’s stock valued at $74,586,000 after purchasing an additional 17,794 shares during the period. Teachers Advisors LLC increased its holdings in Quest Diagnostics by 23.6% in the first quarter. Teachers Advisors LLC now owns 219,065 shares of the medical research company’s stock valued at $21,510,000 after purchasing an additional 41,822 shares during the period. Teacher Retirement System of Texas increased its holdings in Quest Diagnostics by 6.7% in the first quarter. Teacher Retirement System of Texas now owns 30,663 shares of the medical research company’s stock valued at $3,011,000 after purchasing an additional 1,938 shares during the period. Finally, Trustmark National Bank Trust Department increased its holdings in Quest Diagnostics by 2.1% in the first quarter. Trustmark National Bank Trust Department now owns 13,711 shares of the medical research company’s stock valued at $1,346,000 after purchasing an additional 286 shares during the period. Institutional investors own 86.99% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.